10
Participants
Start Date
April 19, 2017
Primary Completion Date
November 4, 2019
Study Completion Date
November 4, 2019
NanoPac® 100 mg/m2
Single intraperitoneal injection of 100 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
NanoPac® 200 mg/m2
Single intraperitoneal injection of 200 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
NanoPac® 300 mg/m2
Single intraperitoneal injection of 300 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
NanoPac® 400 mg/m2
Single intraperitoneal injection of 400 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
Standard of Care Intravenous Chemotherapy
Cytoreductive surgery followed by standard-of-care IV carboplatin and IV paclitaxel treatment
SUNY Downstate, Brooklyn
Magee-Womens Hospital of UPMC, Pittsburgh
Greater Baltimore Medical Center, Baltimore
University of Minnesota, Minneapolis
University of Chicago, Chicago
University of Texas Southwestern, Dallas
Women & Infants Hospital of Rhode Island, Providence
Lead Sponsor
US Biotest, Inc.
INDUSTRY
NanOlogy, LLC
INDUSTRY